Shares of Galena Biopharma Inc (NASDAQ:GALE) ended Thursday session in red amid volatile trading. The shares closed down -0.16 points or -4.55% at $3.36 with 327,075 shares getting traded. Post opening the session at $3.52, the shares hit an intraday low of $3.32 and an intraday high of $3.62 and the price vacillated in this range throughout the day.
Market Cap/Outstanding Shares
The company has a market cap of $611.13 million and the number of outstanding shares have been calculated to be 10.85 million shares.
Performance weekly/monthly/quarterly/yearly in percentage (%)
The performance for the week is valued at -16.00%, resulting in a performance for the month at -37.78%. Therefore, the stated figure displays a quarterly performance of -60.93% and an annual performance of -88.95%.traded up -4.55% on 17 November, 2016 hitting $3.36.
EPS (Earning Per Share )
The EPS of GALE is strolling at -0.13, measuring its EPS growth this year at -5.90%. As a result, the company has an EPS growth of 7.10% for the approaching year. Company’s EPS for the past five years is valued at 17.90%.
Beta factor is stands at 3.11 and Avg. true range is 0.50. Historically, the volatility of this stock is about 10.00% a week and 13.39% a month.
Galena Biopharma Inc (GALE) recently declared that Stephen F. Ghiglieri has been designated as the Company’s Executive Vice President and Chief Financial Officer, effective right away.
“Stephen has 30 years of senior level finance and operating experience, mainly in the life sciences industry, and has been integral to the growth of numerous companies, from emerging stage through commercial approval and market launch,” said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. “Stephen is a welcome addition to our administration team as we restructure our organization and position ourselves to progress our rich clinical pipeline. We are preparing to initiate a pivotal trial next year, and we look forward to providing a corporate update on the progress of all of our programs on our quarterly call next week.”
“I am excited to be joining Galena at this important time in the Company’s history. Galena is presently re-focusing its efforts with a backbone of valuable hematology and immunotherapy assets. I welcome the opportunity to join the team and provide guidance and leadership to assist advance the company through its next stages of development. I believe we have the opportunity to build noteworthyshareholder value by executing on a relatively lower risk clinical and regulatory development program with GALE-401 and supporting ongoing investigator and partner sponsored studies with our immunotherapy assets,” commented, Mr. Ghiglieri.